Can weight-loss drugs slow ageing? Early study shows positive signs

Semaglutide has already transformed the treatment of obesity and type 2 diabetes, with benefits extending to cardiovascular and kidney health in appropriately selected patients. Now, an exploratory study has raised another intriguing possibility—that the medication could influence biological ageing.

Researchers analysing data from a clinical trial found favourable changes in certain DNA-based biomarkers associated with ageing among participants receiving semaglutide. While the findings have generated excitement, experts stress that they are preliminary and should not be interpreted as evidence that the drug slows or reverses the ageing process.

What did the study examine?

The analysis was based on a 32-week randomised, placebo-controlled trial involving 108 adults with HIV-associated lipohypertrophy, a condition characterised by abnormal fat accumulation.

Participants received either weekly semaglutide injections or a placebo. Researchers then assessed changes using epigenetic clocks - research tools that analyse DNA methylation patterns in blood to estimate aspects of biological ageing.

More from Lifestyle

According to the findings, participants treated with semaglutide showed favourable changes in several epigenetic-age estimates, including markers linked to inflammation and organ-related ageing.

Some reports described an average reduction of around 3.1 years in one estimate of biological age.

Biomarkers are not the same as reversing ageing

Despite the encouraging findings, experts emphasise that epigenetic clocks remain research biomarkers rather than direct measures of how old a person's organs are.

"These findings are certainly intriguing because they suggest that semaglutide may influence biological pathways associated with ageing. However, it is important to understand that epigenetic clocks are research tools and not direct measures of biological age," says Dr Anshuman Kaushal, Director - Robotic GI, Minimal Access and Bariatric Surgery, CK Birla Hospital, Gurugram.

"A favourable change in these markers does not mean that the drug reverses ageing, extends lifespan or makes the heart or brain biologically younger. At this stage, it would be scientifically inaccurate to describe semaglutide as an anti-ageing therapy."

What may explain the observed changes?

One of the biggest unanswered questions is whether semaglutide itself influenced these biomarkers or whether the improvements were driven indirectly through weight loss and better metabolic health.

Semaglutide is known to reduce body weight, decrease visceral fat, improve insulin sensitivity and lower inflammation—all factors that may independently affect epigenetic markers.

"It remains unclear whether these changes are a direct pharmacological effect of semaglutide or a consequence of reduced visceral fat, improved metabolic function and lower systemic inflammation," explains Dr Kaushal.

"These mechanisms are closely interconnected, and larger studies specifically designed to answer this question will be needed before any firm conclusions can be drawn."

Important limitations of the study

The findings should also be interpreted within the context of several limitations.

The trial involved only 108 participants, all of whom had HIV-associated lipohypertrophy - a highly specific medical condition. Whether similar results would be observed in people with obesity, type 2 diabetes or the general population remains unknown.

The follow-up period lasted only 32 weeks, making it impossible to determine whether the observed biomarker changes are sustained over time or translate into meaningful clinical benefits.

Furthermore, the analysis has been released as a preprint and has not yet undergone peer review, an essential step in validating scientific research.

Semaglutide's established role remains unchanged

While research into potential anti-ageing effects is at an early stage, semaglutide already has well-established clinical benefits.

The medication is approved for appropriately selected patients with obesity and type 2 diabetes and has demonstrated cardiovascular and renal benefits in certain high-risk populations.

"Semaglutide is an important therapeutic option for patients who meet established clinical indications, particularly for obesity and metabolic disease," says Dr Kaushal.

"However, based on current evidence, it should neither be prescribed nor marketed as an anti-ageing treatment. More robust, long-term and independently replicated studies are required before any claims regarding biological ageing can be made."

The bottom line

The latest findings add an interesting dimension to ongoing research into semaglutide, suggesting that the drug may influence biological-ageing biomarkers measured through DNA methylation.

However, these changes should be viewed as preliminary research signals rather than proof that semaglutide can reverse ageing or extend lifespan.

For now, the study generates an important scientific hypothesis. Whether these biomarker changes ultimately translate into healthier ageing or improved long-term outcomes remains a question that only larger, longer-term clinical trials can answer.